[go: up one dir, main page]

MX2023008190A - Variantes de dominios ch3 genomodificados para la heterodimerización de ch3 preferencial, anticuerpos multi específicos que los comprenden, y sus métodos de fabricación. - Google Patents

Variantes de dominios ch3 genomodificados para la heterodimerización de ch3 preferencial, anticuerpos multi específicos que los comprenden, y sus métodos de fabricación.

Info

Publication number
MX2023008190A
MX2023008190A MX2023008190A MX2023008190A MX2023008190A MX 2023008190 A MX2023008190 A MX 2023008190A MX 2023008190 A MX2023008190 A MX 2023008190A MX 2023008190 A MX2023008190 A MX 2023008190A MX 2023008190 A MX2023008190 A MX 2023008190A
Authority
MX
Mexico
Prior art keywords
variants
genomodified
heterodimerization
preferential
domains
Prior art date
Application number
MX2023008190A
Other languages
English (en)
Inventor
Michael Benjamin Battles
Robert Pejchal
Caitlin Stein
Julia Mccreary
Arvind Sivasubramanian
Kyle Barlow
Original Assignee
Adimab Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adimab Llc filed Critical Adimab Llc
Publication of MX2023008190A publication Critical patent/MX2023008190A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Se proporcionan polipéptidos de variante de dominio CH3 que preferentemente forman heterodímeros CH3-CH3 sobre homodímeros CH3-CH3. Tales variantes de dominios CH3 pueden usarse para promover el emparejamiento de Fc deseado, proporcionando así un desarrollo eficiente de anticuerpos biespecíficos y multiespecíficos, así como también fusiones de Fc de formatos diferentes. También se proporcionan métodos para producir anticuerpos biespecíficos mediante el uso de tales variantes de dominios CH3 y para producir bibliotecas que contienen tales variantes de dominios CH3.
MX2023008190A 2021-01-11 2022-01-11 Variantes de dominios ch3 genomodificados para la heterodimerización de ch3 preferencial, anticuerpos multi específicos que los comprenden, y sus métodos de fabricación. MX2023008190A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163136120P 2021-01-11 2021-01-11
PCT/US2022/012038 WO2022150785A2 (en) 2021-01-11 2022-01-11 Variant ch3 domains engineered for preferential ch3 heterodimerization, multi-specific antibodies comprising the same, and methods of making thereof

Publications (1)

Publication Number Publication Date
MX2023008190A true MX2023008190A (es) 2023-09-28

Family

ID=82358776

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023008190A MX2023008190A (es) 2021-01-11 2022-01-11 Variantes de dominios ch3 genomodificados para la heterodimerización de ch3 preferencial, anticuerpos multi específicos que los comprenden, y sus métodos de fabricación.

Country Status (10)

Country Link
US (1) US20250223379A1 (es)
EP (1) EP4271714A4 (es)
JP (1) JP2024503034A (es)
KR (1) KR20230162775A (es)
CN (1) CN117440969A (es)
AU (1) AU2022206475A1 (es)
CA (1) CA3204625A1 (es)
IL (1) IL304147A (es)
MX (1) MX2023008190A (es)
WO (1) WO2022150785A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025502189A (ja) * 2022-01-11 2025-01-24 アディマブ， エルエルシー 優先的ｃｈ３ヘテロ二量体化のために操作されたバリアントｃｈ３ドメイン、それを含む多重特異性抗体、及びその作製方法
WO2024242490A1 (ko) * 2023-05-24 2024-11-28 삼성바이오로직스 주식회사 Ch3 도메인 변이체 또는 이를 포함하는 이중 특이적 항체
EP4520768A1 (en) 2023-09-06 2025-03-12 BioNTech SE Vhh-ch3 fusion proteins

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX368932B (es) * 2009-06-26 2019-10-22 Regeneron Pharma Anticuerpos biespecificos facilmente aislados con formato de inmunoglobulina original.
US20130177555A1 (en) * 2010-08-13 2013-07-11 Medimmune Limited Monomeric Polypeptides Comprising Variant FC Regions And Methods Of Use
WO2013033008A2 (en) * 2011-08-26 2013-03-07 Merrimack Pharmaceuticals, Inc. Tandem fc bispecific antibodies
KR102052774B1 (ko) * 2011-11-04 2019-12-04 자임워크스 인코포레이티드 Ｆｃ 도메인 내의 돌연변이를 갖는 안정한 이종이합체 항체 설계
ES2743399T3 (es) * 2012-04-20 2020-02-19 Merus Nv Métodos y medios para la producción de moléculas heterodiméricas similares a Ig
BR112016016416A2 (pt) * 2014-01-15 2017-10-03 Hoffmann La Roche VARIANTES DE REGIÕES-"Fc" COM 'FcRn' MODIFICADAS E PROPRIEDADES DE LIGAÇÃO DE PROTEÍNA "A" MANTIDAS
MA41375A (fr) * 2015-01-22 2017-11-28 Lilly Co Eli Anticorps igg bispécifiques et leurs procédés de préparation
JP7103751B6 (ja) * 2015-04-28 2022-08-15 ザイムワークス，インコーポレイテッド 修飾された抗原結合ポリペプチド構築物及びその使用
KR101851380B1 (ko) * 2015-10-12 2018-04-23 아주대학교산학협력단 효모접합을 이용한 항체 ch3 도메인 이종이중체 돌연변이쌍 제조 방법 및 이에 의하여 제조된 ch3 돌연변이체 쌍
IL265605B2 (en) * 2016-09-29 2024-06-01 Beijing Hanmi Pharmaceutical Co Ltd Heterodimeric immunoglobulin constructs, pharmaceutical composition comprising the same, use and preparation methods thereof
EP3576789B1 (en) * 2017-02-01 2024-12-11 Zhejiang Shimai Pharmaceutical Co., Ltd. MONOMERIC HUMAN IgG1 Fc AND BISPECIFIC ANTIBODIES
EA202091977A1 (ru) * 2018-05-28 2021-02-09 Драгонфлай Терапьютикс, Инк. Мультиспецифические связывающие белки, которые связывают cd33, nkg2d и cd16, и способы применения
TWI874341B (zh) * 2018-12-18 2025-03-01 美商健生生物科技公司 產生異二聚體抗體之方法
WO2020252264A1 (en) * 2019-06-12 2020-12-17 AskGene Pharma, Inc. Novel il-15 prodrugs and methods of use thereof
CA3140318A1 (en) * 2019-06-19 2020-12-24 Johannes Auer Method for the generation of a bivalent, bispecific antibody expressing cell by targeted integration of multiple expression cassettes in a defined organization
WO2021001289A1 (en) * 2019-07-02 2021-01-07 F. Hoffmann-La Roche Ag Immunoconjugates comprising a mutant interleukin-2 and an anti-cd8 antibody

Also Published As

Publication number Publication date
CN117440969A (zh) 2024-01-23
CA3204625A1 (en) 2022-07-14
EP4271714A2 (en) 2023-11-08
JP2024503034A (ja) 2024-01-24
IL304147A (en) 2023-09-01
WO2022150785A3 (en) 2022-08-11
AU2022206475A1 (en) 2023-08-17
KR20230162775A (ko) 2023-11-28
US20250223379A1 (en) 2025-07-10
WO2022150785A2 (en) 2022-07-14
EP4271714A4 (en) 2025-06-25

Similar Documents

Publication Publication Date Title
MX2023008190A (es) Variantes de dominios ch3 genomodificados para la heterodimerización de ch3 preferencial, anticuerpos multi específicos que los comprenden, y sus métodos de fabricación.
BR112015021462A2 (pt) anticorpos biespecíficos anti-c-met tandem fc
CO2021008696A2 (es) Moléculas agonistas de unión al antígeno cd28 que actúan sobre el tumor
MX2022011472A (es) Formato de anticuerpo multiespecifico heterodimerico.
ECSP20075234A (es) Anticuerpos anti-tmeff2 monoespecíficos y multiespecíficos y sus usos
PE20160157A1 (es) Moduladores de los receptores de estrogeno y sus usos
MX2022000302A (es) Moleculas de union que inhiben el crecimiento del cancer.
CR20170596A (es) Derivados de amidas policiclicas como inhibidores de cdk9
MX2022003744A (es) Variantes del dominio ch1 modificadas geneticamente para el emparejamiento preferencial a cadenas ligeras y anticuerpos multiespecíficos que comprenden las mismas.
CR20160147A (es) Formulaciones de anticuerpos
ECSP16061758A (es) Moduladores de tetrahidropiridopirazinas de gpr6
CO2018003452A2 (es) Anticuerpos biespecíficos contra el cd20 humano y el receptor de transferrina humano y métodos de uso
ECSP099692A (es) Ligandos de receptor de vainilloide novedosos y su uso de los mismos para la produccion de sustancias farmaceuticas
CU20180033A7 (es) Conjugados de anticuerpo que comprenden un agonista del receptor tipo toll
ES2930298T3 (es) Moduladores del receptor de glucocorticoides de azadecalina condensada con heteroaril-cetona
MX391041B (es) Proteinas que contienen fc de anticuerpos heterodimericos y metodos para produccion de las mismas.
CO2023000055A2 (es) Moléculas agonistas de unión al antígeno cd28 que se dirigen a her2
CO2022006800A2 (es) Métodos de fabricación de linfocitos t-car
MX2016008196A (es) Anticuerpos y metodos de uso.
AR094403A1 (es) Terapia de combinación de anticuerpos anti-her3
AR113092A1 (es) Métodos para fabricar receptores de antígeno quiméricos biespecíficos anti-cd307e y anti-bcma y usos de los mismos
MX2017006565A (es) Esteroides 6.alfa.-alquil-3,7-diona como intermedios para la produccion de moduladores esteroides del receptor x farnesoide (fxr).
AR113223A1 (es) Anticuerpo monoclonal para pd-l1
MX2021007141A (es) Sintesis de gamma-carbolinas fusionadas con heterociclo sustituido.
MX2023006817A (es) Composiciones y metodos relacionados con anticuerpos activados por tumores dirigidos a psma y antigenos de celulas efectoras.